Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Decreases Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. decreased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 12.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 376,496 shares of the company's stock after selling 52,896 shares during the period. Janux Therapeutics makes up 2.0% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s holdings, making the stock its 17th biggest position. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned 0.64% of Janux Therapeutics worth $10,165,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. increased its position in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Janux Therapeutics in the 4th quarter worth approximately $59,000. GAMMA Investing LLC raised its stake in shares of Janux Therapeutics by 1,574.0% during the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock valued at $45,000 after acquiring an additional 1,574 shares during the last quarter. FNY Investment Advisers LLC lifted its stake in shares of Janux Therapeutics by 6,928.6% in the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock valued at $66,000 after purchasing an additional 2,425 shares during the period. Finally, KBC Group NV purchased a new position in Janux Therapeutics in the 1st quarter worth approximately $66,000. Institutional investors own 75.39% of the company's stock.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total value of $106,755.99. Following the sale, the insider directly owned 82,139 shares in the company, valued at approximately $2,630,912.17. The trade was a 3.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.10% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial started coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They set an "outperform" rating and a $65.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Janux Therapeutics presently has a consensus rating of "Buy" and an average target price of $91.89.

Janux Therapeutics Stock Down 3.9%

NASDAQ JANX traded down $1.00 on Friday, hitting $24.97. The stock had a trading volume of 402,702 shares, compared to its average volume of 942,619. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of -18.41 and a beta of 2.86. The company's 50-day moving average is $24.77 and its two-hundred day moving average is $30.69.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.